伊伐布雷定治疗儿童扩张型心肌病伴症状性慢性心力衰竭
本研究为随机双盲安慰剂对照II/III期试验,纳入116例稳定心衰治疗的儿童扩张型心肌病患者,评估伊伐布雷定剂量反应关系。主要终点(心率较基线降低≥20%且不引起心动过缓或症状)在伊伐布雷定组70%达成,安慰剂组12%(OR 17.24,p<0.0001);12个月时左室射血分数增加伊伐布雷定组13.5% vs 安慰剂组6.9%(p=0.024)。伊伐布雷定安全降低静息心率,心率效应可变,强调剂量滴定的重要性。
要点
- 伊伐布雷定使70%患儿达到主要心率终点,安慰剂组仅12%。
- 12个月左室射血分数增加伊伐布雷定组13.5%,安慰剂组6.9%。
- 心率效应可变,需个体化剂量滴定,不良事件频率与安慰剂相似。
核心结论
- 伊伐布雷定安全降低儿童扩张型心肌病伴症状性慢性心衰的静息心率,并改善左室射血分数,临床状态和生活质量呈有利趋势。
研究设计与样本
- 随机、双盲、安慰剂对照II/III期研究,随访12个月,纳入116例接受稳定心衰治疗的儿童患者,随机分配至伊伐布雷定或安慰剂。
主要发现
- 主要终点达成率伊伐布雷定组70%(51/73) vs 安慰剂组12%(5/41),OR 17.24,p<0.0001。
- 12个月左室射血分数增加伊伐布雷定组13.5% vs 安慰剂组6.9%,p=0.024。
- 12个月NYHA/Ross心功能分级改善伊伐布雷定组38% vs 安慰剂组25%,p=0.24。
- 生活质量改善伊伐布雷定组 vs 安慰剂组p=0.053。
- NT-proBNP水平两组下降相似,不良事件频率相似。
临床怎么用
- 对于儿童扩张型心肌病伴症状性慢性心衰,可考虑使用伊伐布雷定降低心率,但需进行剂量滴定以达目标心率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Heart rate reduction as a therapeutic target has been investigated in adults with heart failure (HF). Ivabradine has shown promising efficacy, but has not been evaluated in children. Currently, treatment recommendations for chronic pediatric HF are based mainly on chronic HF guidelines for adults. OBJECTIVES: The authors explored the dose-response relationship of ivabradine in children with dilated cardiomyopathy and symptomatic chronic HF. The primary endpoint was ≥20% reduction in heart rate from baseline without inducing bradycardia or symptoms. METHODS: This was a randomized, double-blind, placebo-controlled, phase II/III study with 12 months of follow-up. Children (n = 116) receiving stable HF therapy were randomized to either ivabradine or placebo. After an initial titration period, the dose was adjusted to attain the primary endpoint. Left ventricular function (echocardiography), clinical status (New York Heart Association functional class or Ross class), N-terminal pro-B-type natriuretic peptide, and quality of life (QOL) were assessed. RESULTS: The primary endpoint was reached by 51 of 73 children taking ivabradine (70%) versus 5 of 41 taking placebo (12%) at varying doses (odds ratio: 17.24; p < 0.0001). Between baseline and 12 months, there was a greater increase in left ventricular ejection fraction in patients taking ivabradine than placebo (13.5% vs. 6.9%; p = 0.024). New York Heart Association functional class or Ross class improved more with ivabradine at 12 months than placebo (38% vs. 25%; p = 0.24). There was a trend toward improvement in QOL for ivabradine versus placebo (p = 0.053). N-terminal pro-B-type natriuretic peptide levels decreased similarly in both groups. Adverse events were reported at similar frequencies for ivabradine and placebo. CONCLUSIONS: Ivabradine safely reduced the resting heart rate of children with chronic HF and dilated cardiomyopathy. Ivabradine's effect on heart rate was variable, highlighting the importance of dose titration. Ivabradine treatment improved left ventricular ejection fraction, and clinical status and QOL showed favorable trends. (Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure from ages 6 months to 18 years; ISRCTN60567801).
引用
- Bonnet D, Berger F, Jokinen E, et al. Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure. J Am Coll Cardiol. 2017. PMID: 28859790. doi:10.1016/j.jacc.2017.07.725
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。